Sandoz-JPM-2026-Conference-Presentation.pdf

1、Pioneering access for patientsRichard Saynor,CEOJ.P.Morgan Healthcare ConferenceJanuary 2026DisclaimerThis presentation contains forward-looking statements,which offerno guarantee with regard to future performance.These statements are made on the basis of managements viewsand assumptions regarding f

2、uture events and business performanceat the time the statements are made.They are subject to risks anduncertainties including,but not confined to,future global economicconditions,exchange rates,legal provisions,market conditions,activities by competitors and other factors outside of the control ofSa

3、ndoz.Should one or more of these risks or uncertaintiesmaterialize or should underlying assumptions prove incorrect,actualoutcomes may vary materially from those forecasted or expected.Each forward-looking statement speaks only as of the date of theparticular statement,and Sandoz undertakes no oblig

4、ation topublicly update or revise any forward-looking statements,except asrequired by law.This presentation includes non-IFRS financial measures as definedby Sandoz.An explanation of non-IFRS measures can be found inthe Supplementary financial information of the Half-Year Report2025.Certain figures

5、contained in this presentation,including financialinformation presented in billions or millions,certain operating dataand percentages describing financial information or market shares,have been subject to rounding.Dollar values and percentages maynot agree to totals.JP Morgan Healthcare ConferenceAg

6、endaDocument title3Establishing our edgeExecuting with impactShaping the futureQuestionsEstablishing our edge5Sandoz uniqueness:scale,trust and impactThree pillars defining leadership in biosimilars and generics Focused model;trusted execution Only pure-play biosimilars andgenerics company with glob